IL138160A0 - Quinoline derivatives - Google Patents

Quinoline derivatives

Info

Publication number
IL138160A0
IL138160A0 IL13816099A IL13816099A IL138160A0 IL 138160 A0 IL138160 A0 IL 138160A0 IL 13816099 A IL13816099 A IL 13816099A IL 13816099 A IL13816099 A IL 13816099A IL 138160 A0 IL138160 A0 IL 138160A0
Authority
IL
Israel
Prior art keywords
quinoline derivatives
quinoline
derivatives
Prior art date
Application number
IL13816099A
Other languages
English (en)
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of IL138160A0 publication Critical patent/IL138160A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
IL13816099A 1998-04-27 1999-04-26 Quinoline derivatives IL138160A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9801474A SE9801474D0 (sv) 1998-04-27 1998-04-27 Quinoline Derivatives
PCT/SE1999/000676 WO1999055678A1 (en) 1998-04-27 1999-04-26 Quinoline derivatives

Publications (1)

Publication Number Publication Date
IL138160A0 true IL138160A0 (en) 2001-10-31

Family

ID=20411103

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13816099A IL138160A0 (en) 1998-04-27 1999-04-26 Quinoline derivatives
IL138160A IL138160A (en) 1998-04-27 2000-08-30 Quinoline derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL138160A IL138160A (en) 1998-04-27 2000-08-30 Quinoline derivatives

Country Status (33)

Country Link
EP (1) EP1073639B1 (sv)
JP (1) JP4045069B2 (sv)
KR (1) KR100571534B1 (sv)
CN (1) CN1113057C (sv)
AP (1) AP1293A (sv)
AT (1) ATE228505T1 (sv)
AU (1) AU747550B2 (sv)
BR (1) BR9909925B1 (sv)
CA (1) CA2329788C (sv)
CZ (1) CZ297439B6 (sv)
DE (1) DE69904162T2 (sv)
DK (1) DK1073639T3 (sv)
EE (1) EE04275B1 (sv)
ES (1) ES2188242T3 (sv)
HK (1) HK1036618A1 (sv)
HR (1) HRP20000726B1 (sv)
HU (1) HU227709B1 (sv)
ID (1) ID26277A (sv)
IL (2) IL138160A0 (sv)
IS (1) IS2082B (sv)
ME (1) ME00870B (sv)
NO (1) NO315606B1 (sv)
NZ (1) NZ506641A (sv)
OA (1) OA11547A (sv)
PL (1) PL190441B1 (sv)
PT (1) PT1073639E (sv)
RS (1) RS50029B (sv)
RU (1) RU2197481C2 (sv)
SE (1) SE9801474D0 (sv)
TR (1) TR200003061T2 (sv)
UA (1) UA60354C2 (sv)
WO (1) WO1999055678A1 (sv)
ZA (1) ZA200004601B (sv)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
KR100908655B1 (ko) 2002-11-27 2009-07-21 엘지디스플레이 주식회사 데이터 공급시간의 변조방법과 이를 이용한액정표시장치의 구동방법 및 장치
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
BRPI0516383A (pt) 2004-12-21 2008-09-02 Serono Lab derivados cìclicos de sulfonil amino e o uso dos mesmos
EP1844032B1 (en) 2005-01-31 2011-07-13 Merck Serono SA N-hydroxyamide derivatives and use thereof
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 jnk 억제제
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
JP2009507003A (ja) 2005-09-01 2009-02-19 アレス トレーディング ソシエテ アノニム 視神経炎の治療
UA92761C2 (ru) * 2005-10-19 2010-12-10 Тева Фармасьютикл Индастриз, Лтд. Кристаллы лаквинимода натрия и способ их изготовления
AU2007258366B2 (en) 2006-06-12 2012-10-25 Active Biotech, Ab Stable laquinimod preparations
SI2234485T1 (sl) 2007-12-20 2014-03-31 Teva Pharmaceutical Industries Ltd. Stabilni lakvinimodni pripravki
EA021227B1 (ru) * 2008-09-03 2015-05-29 Тева Фармасьютикал Индастриз Лтд. 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
ES2564931T3 (es) * 2009-07-30 2016-03-30 Teva Pharmaceutical Industries Ltd. Tratamiento de enfermedad de Crohn con laquinimod
DK2467372T3 (en) * 2009-08-10 2016-08-22 Teva Pharma TREATMENT OF BDNF-RELATED DISEASES USING LAQUINIMOD
SG183515A1 (en) * 2010-03-03 2012-10-30 Teva Pharma Treatment of lupus arthritis using laquinimod
PT2542079E (pt) 2010-03-03 2014-07-18 Teva Pharma Tratamento da artrite reumatoide com uma combinação de laquinimod e metotrexato
PE20130613A1 (es) 2010-03-03 2013-06-23 Teva Pharma Tratamiento de lupus nefritis usando laquinimod
WO2011116091A1 (en) 2010-03-17 2011-09-22 Novartis Ag Dispenser
KR20130092558A (ko) 2010-07-09 2013-08-20 테바 파마슈티컬 인더스트리즈 리미티드 중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도
ES2563208T3 (es) * 2010-07-09 2016-03-11 Active Biotech Ab Método para fabricar quinolina-3-carboxamidas
US20120010239A1 (en) * 2010-07-09 2012-01-12 Ulf Tomas Fristedt 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
EP2444086A1 (en) 2010-10-22 2012-04-25 Almirall, S.A. Combinations comprising DHODH inhibitors and COX inhibitors
US8889627B2 (en) 2011-10-12 2014-11-18 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
US9284276B2 (en) 2012-02-16 2016-03-15 Teva Pharmaceutical Industries, Ltd. N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療gaba媒介之疾病之拉喹莫德(laquinimod)
MX2015005632A (es) * 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
RU2545056C2 (ru) * 2012-12-10 2015-03-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здавоохранения и социального развития Российской Федерации (ГБОУ ВПО ПГФА Минздравсоцразвития России) Противовоспалительное и анальгетическое средство на основе изопропиламида 1,2-дигидро-1н-2-оксоцинхониновой кислоты
AU2014216199A1 (en) * 2013-02-15 2015-09-03 Teva Pharmaceutical Industries Ltd. Treatment of progressive forms of multiple sclerosis with laquinimod
NZ630427A (en) 2013-03-14 2017-06-30 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
KR102533033B1 (ko) 2014-09-23 2023-05-15 액티브 바이오테크 에이비 다발성 골수종의 치료에 사용하기 위한 퀴놀린 카르복사미드
MX2017006110A (es) 2014-11-19 2017-07-27 Active Biotech Ab Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
CA3157394A1 (en) 2019-12-19 2021-06-24 Helena ERIKSSON Compounds for treatment of eye diseases associated with excessive vascularisation
MX2022010327A (es) 2020-03-03 2022-11-09 Active Biotech Ab Tasquinimod o una sal farmaceuticamente aceptable del mismo para el uso en una terapia combinada.
CA3185531A1 (en) 2020-07-23 2022-01-27 Rebekka Katharina Marita SCHNEIDER-KRAMANN S100 proteins as novel therapeutic targets in myeloproliferative neoplasms
US20240091215A1 (en) 2021-01-18 2024-03-21 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
CA3218977A1 (en) 2021-05-25 2022-12-01 Hans Wannman A plurality of tasquinimod particles and use thereof
IL309486A (en) 2021-07-02 2024-02-01 Active Biotech Ab A pharmacy product containing tesquinimod and a method for evaluating the cleanliness of this product

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives

Also Published As

Publication number Publication date
CA2329788A1 (en) 1999-11-04
NO20005254D0 (no) 2000-10-19
AU747550B2 (en) 2002-05-16
CA2329788C (en) 2004-11-23
HUP0102084A3 (en) 2002-12-28
WO1999055678A1 (en) 1999-11-04
PL190441B1 (pl) 2005-12-30
CN1113057C (zh) 2003-07-02
RU2197481C2 (ru) 2003-01-27
ME00870B (me) 2008-11-28
EP1073639A1 (en) 2001-02-07
NZ506641A (en) 2002-03-28
CZ20003849A3 (cs) 2001-03-14
TR200003061T2 (tr) 2001-01-22
AP2000001933A0 (en) 2000-12-31
NO20005254L (no) 2000-12-27
RS50029B (sr) 2008-11-28
YU61200A (sh) 2003-07-07
EP1073639B1 (en) 2002-11-27
EE200000613A (et) 2002-04-15
DK1073639T3 (da) 2003-03-24
BR9909925A (pt) 2001-01-09
HUP0102084A2 (hu) 2001-11-28
CZ297439B6 (cs) 2006-12-13
NO315606B1 (no) 2003-09-29
DE69904162T2 (de) 2003-08-21
ID26277A (id) 2000-12-14
ATE228505T1 (de) 2002-12-15
IS5615A (is) 2000-08-31
HU227709B1 (en) 2011-12-28
JP4045069B2 (ja) 2008-02-13
BR9909925B1 (pt) 2010-09-21
HRP20000726B1 (en) 2009-04-30
PT1073639E (pt) 2003-04-30
HRP20000726A2 (en) 2001-04-30
ES2188242T3 (es) 2003-06-16
IL138160A (en) 2006-04-10
JP2002513006A (ja) 2002-05-08
KR100571534B1 (ko) 2006-04-14
CN1298393A (zh) 2001-06-06
AU4301399A (en) 1999-11-16
DE69904162D1 (de) 2003-01-09
IS2082B (is) 2006-02-15
AP1293A (en) 2004-08-30
OA11547A (en) 2004-05-24
PL343420A1 (en) 2001-08-13
ZA200004601B (en) 2002-02-27
EE04275B1 (et) 2004-04-15
SE9801474D0 (sv) 1998-04-27
UA60354C2 (uk) 2003-10-15
HK1036618A1 (en) 2002-01-11

Similar Documents

Publication Publication Date Title
IL143782A0 (en) Quinoline derivatives
PL343420A1 (en) Quinoline derivatives
AP2001002041A0 (en) Quinoline derivatives
GB9904103D0 (en) Quinoline derivatives
HK1038746A1 (en) 1,2-annelated quinoline derivatives
AP2001002040A0 (en) Quinoline derivatives
IL141226A0 (en) 1h-imidazopyridine derivatives
PL345540A1 (en) Thiobenzimidazole derivatives
HU9900120D0 (en) Benzosulfone derivatives
GB9910384D0 (en) Alpha-ketoamide derivatives
EG23802A (en) 2-Phenylpyran-4-one derivatives
GB9827729D0 (en) Thieno-indole derivatives
EG24161A (en) Carbostyril derivatives
EP1061912A4 (en) PHENANTHROFURANDERIVATE
IL139276A0 (en) Cyclohexenondioxthio chromanoyl derivatives
HK1042478A1 (zh) 2-氧代-2h-喹啉衍生物
GB9904102D0 (en) Quinoline derivatives
GB9904104D0 (en) Quinoline derivatives
GB9904105D0 (en) Quinoline derivatives
GB9816279D0 (en) Arylthiazolidinedione derivatives
SI1051395T1 (sl) N-hidroksiformamidni derivati

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed